We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other psychedelic ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.

The FDA approved Johnson & Johnson’s Spravato as a monotherapy for adults with treatment-resistant depression. The nasal spray drug’s initial approval in 2019 covered its use in combination ...

Shares in Axsome Therapeutics have rocketed on FDA approval ... to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience ... blockbuster schizophrenia drug Invega and the nasal spray depression drug Spravato. The pharma giant ...

A month into his role as health and human services secretary, Robert F. Kennedy Jr.'s moves on vaccines have worried health ...

Johnson & Johnson has priced its new ... 25% and 52% cheaper to meet its value threshold. The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants. The Food and Drug ...

Healthcare & Pharmaceuticalscategory· March 7, 2025 US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg ... due to low effectiveness Johnson & Johnson will stop late ...